Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ...

SaverOne 2014 (SVRE) announced the award of a new contract with Teva Pharmaceutical (TEVA), to install the SaverOne System across its entire ...

Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name ...

Teva Pharma Industries Ltd ADR (NYSE: TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

KBC Group NV lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 43.2% during the 4th quarter, Holdings Channel reports. The fund owned 37,163 shares of the ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...